In a nutshell This study examined how effective and safe tislelizumab (BGB-A317) is for patients with relapsed or refractory classical Hodgkin's lymphoma (cHL). The authors concluded that most patients responded to tislelizumab but also experienced side effects. Some background cHL is often treated with chemotherapy or stem cell...
Read MoreCurrent treatment status-Undergoing active treatment-Partial response Posts on Medivizor
Evaluating combination CAR-T cell therapy for recurrent or treatment-resistant multiple myeloma
In a nutshell This study evaluated the safety and effectiveness of combining two T-cell therapies for multiple myeloma (MM) that has come back or stopped responding to treatment. This study concluded that this treatment showed promising effectiveness for these patients. Some background Treatment for patients with MM that has come back (relapsed)...
Read MoreLooking for patients with relapsed or unresponsive multiple myeloma to try allogeneic CAR-T cell therapy
In a nutshell This trial is evaluating the safety and effectiveness of allogeneic CAR-T cell therapy (ALLO-715) in patients with multiple myeloma (MM) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This trial is recruiting in Denver, CO. The details Chimeric...
Read MoreEvaluating the TLI-ATG conditioning regimen before allogeneic stem cell transplantation in patients with lymphoma or leukemia
In a nutshell This study evaluated the safety and effectiveness of total lymphoid irradiation and anti-thymocyte globulin (TLI-ATG) conditioning before stem cell transplantation (SCT) in patients with lymphoma or leukemia. This study concluded that this regimen was well-tolerated and effective, especially for patients who had multiple lines of prior...
Read MoreEvaluating nivolumab plus brentuximab vedotin for patients with relapsed or unresponsive primary mediastinal large B-cell lymphoma
In a nutshell This study evaluated nivolumab (Opdivo) plus brentuximab vedotin (Adcetris) in patients with relapsed or unresponsive primary mediastinal B-cell lymphoma (PMBCL). This study concluded that this combination is promising and was well-tolerated. Some background PMBCL is a rare but aggressive type of non-Hodgkin’s lymphoma (NHL)....
Read MoreLooking for patients with relapsed or unresponsive classical Hodgkin lymphoma to test a new treatment combination
In a nutshell This study is evaluating how well a new chemoimmunotherapy regimen works in treating patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer after treatment. This study...
Read MoreUsing alpha-interferon to treat residual chronic myeloid leukemia after transplantation
In a nutshell This study looked at the effectiveness of interferon-alpha (IntronA) treatment in patients with chronic myeloid leukemia (CML) with residual disease after transplantation. Researchers found that this treatment may be useful in patients with signs of disease after transplant. Some background Chronic myeloid leukemia is a cancer...
Read MoreEvaluating high-dose etoposide before stem cell transplantation for patients with unresponsive diffuse large B cell lymphoma
In a nutshell This study evaluated the outcomes of patients with unresponsive diffuse B-cell lymphoma (DLBCL) after treatment with high-dose etoposide (Etopophos) and a stem cell transplant (SCT). This study concluded that this regimen was effective for some of these patients, namely those who responded to etoposide treatment. Some background DLBCL is...
Read MoreEvaluating quality of life after pembrolizumab treatment for classical Hodgkin lymphoma
In a nutshell This phase 2 study evaluated the impact of pembrolizumab (Keytruda) on the quality of life of patients with classical Hodgkin’s lymphoma (cHL) that has come back or stopped responding to treatment. This study concluded that the overall quality of life and health status was improved for these patients. Some background Most patients...
Read MoreEvaluating brentuximab vedotin plus high-dose bendamustine for relapsed or unresponsive Hodgkin lymphoma
In a nutshell This study examined how well brentuximab vedotin (Adcetris) plus high-dose bendamustine (Treanda) worked in patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL). This study concluded that this regimen was highly effective for these patients. Some background After initial treatment, many patients with cHL...
Read MoreChemotherapy regimens for patients with relapsed or unresponsive acute myeloid leukemia
In a nutshell This study aimed to compare outcomes of fludarabine–treosulfan (FT), thiotepa–busulfan–fludarabine (TBF), and fludarabine, Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide (FLAMSA) in the treatment of patients with relapsed or unresponsive acute myeloid leukemia (AML). The study found that all...
Read MoreEvaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma
In a nutshell This study evaluated isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...
Read More
